Pernille Tine Jensen

Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Use of PROM during follow-up of patients with ovarian cancer : the PROMova study protocol. / Kargo, Anette Stolberg; Coulter, Angela; Lindemann, Kristina; Jensen, Pernille Tine; Hjøllund, Niels Henrik; Mosgaard, Berit Jul; Steffensen, Karina Dahl.

I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Bind 30, Nr. 9, 09.2020, s. 1444-1449.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Kargo, AS, Coulter, A, Lindemann, K, Jensen, PT, Hjøllund, NH, Mosgaard, BJ & Steffensen, KD 2020, 'Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, bind 30, nr. 9, s. 1444-1449. https://doi.org/10.1136/ijgc-2020-001528

APA

Kargo, A. S., Coulter, A., Lindemann, K., Jensen, P. T., Hjøllund, N. H., Mosgaard, B. J., & Steffensen, K. D. (2020). Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 30(9), 1444-1449. https://doi.org/10.1136/ijgc-2020-001528

CBE

Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD. 2020. Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 30(9):1444-1449. https://doi.org/10.1136/ijgc-2020-001528

MLA

Kargo, Anette Stolberg o.a.. "Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol". International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2020, 30(9). 1444-1449. https://doi.org/10.1136/ijgc-2020-001528

Vancouver

Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ o.a. Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2020 sep;30(9):1444-1449. https://doi.org/10.1136/ijgc-2020-001528

Author

Kargo, Anette Stolberg ; Coulter, Angela ; Lindemann, Kristina ; Jensen, Pernille Tine ; Hjøllund, Niels Henrik ; Mosgaard, Berit Jul ; Steffensen, Karina Dahl. / Use of PROM during follow-up of patients with ovarian cancer : the PROMova study protocol. I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2020 ; Bind 30, Nr. 9. s. 1444-1449.

Bibtex

@article{80951641b9764363ae8fd21a30211f26,
title = "Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol",
abstract = "BACKGROUND: There is a paucity of high-level evidence on the optimal follow-up of patients with ovarian cancer after primary treatment. A debate is ongoing on the extent to which follow-up should consider patient preferences and patient-reported outcome measures. Incorporation of patient-reported outcome measures supports the dialog between patient and clinician and may be instrumental in symptom monitoring and detection of underlying issues, especially when used actively during the clinical consultation. PRIMARY OBJECTIVE AND ENDPOINT: The PROMova study aims to assess whether proactive use of patient-reported outcome measures during follow-up care increases patient involvement as perceived by the patient compared with standard care. Another objective is to measure satisfaction with the care provided. STUDY HYPOTHESIS: It is hypothesized that proactive use of patient-reported outcome measures during the clinical encounter will improve patients' experience of involvement in follow-up care. TRIAL DESIGN: PROMova is a multi-center, observational cohort study collecting data from eight departments in Denmark. Five departments use the patient-reported outcome measures proactively during the consultation and three provide standard care. Participants are followed up with patient-reported outcome measures for up to 3 years. The patient-reported outcome measures package comprises EORTC QLQ-C30, EORTC QLQ-OV28, a questionnaire screening tool for recurrence, CollaboRATE, and selected questions from the Patient Experience Questionnaire. MAJOR INCLUSION/EXCLUSION CRITERIA: Patients older than 18 years diagnosed with ovarian, fallopian tube, or primary peritoneal cancer are eligible when entering the follow-up program after primary treatment. Participants must be able to speak and read Danish. SAMPLE SIZE: 223 patients with ovarian cancer. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The protocol closed for enrollment in 2019. Publication of final results is expected in spring 2022. TRIAL REGISTRATION: PROMova was registered with ClinicalTrials.gov November 2016 Identifier: NCT02916875.",
keywords = "medical oncology, ovarian cancer, ovarian neoplasms, quality of life (PRO)/palliative care",
author = "Kargo, {Anette Stolberg} and Angela Coulter and Kristina Lindemann and Jensen, {Pernille Tine} and Hj{\o}llund, {Niels Henrik} and Mosgaard, {Berit Jul} and Steffensen, {Karina Dahl}",
year = "2020",
month = sep,
doi = "10.1136/ijgc-2020-001528",
language = "English",
volume = "30",
pages = "1444--1449",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "9",

}

RIS

TY - JOUR

T1 - Use of PROM during follow-up of patients with ovarian cancer

T2 - the PROMova study protocol

AU - Kargo, Anette Stolberg

AU - Coulter, Angela

AU - Lindemann, Kristina

AU - Jensen, Pernille Tine

AU - Hjøllund, Niels Henrik

AU - Mosgaard, Berit Jul

AU - Steffensen, Karina Dahl

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: There is a paucity of high-level evidence on the optimal follow-up of patients with ovarian cancer after primary treatment. A debate is ongoing on the extent to which follow-up should consider patient preferences and patient-reported outcome measures. Incorporation of patient-reported outcome measures supports the dialog between patient and clinician and may be instrumental in symptom monitoring and detection of underlying issues, especially when used actively during the clinical consultation. PRIMARY OBJECTIVE AND ENDPOINT: The PROMova study aims to assess whether proactive use of patient-reported outcome measures during follow-up care increases patient involvement as perceived by the patient compared with standard care. Another objective is to measure satisfaction with the care provided. STUDY HYPOTHESIS: It is hypothesized that proactive use of patient-reported outcome measures during the clinical encounter will improve patients' experience of involvement in follow-up care. TRIAL DESIGN: PROMova is a multi-center, observational cohort study collecting data from eight departments in Denmark. Five departments use the patient-reported outcome measures proactively during the consultation and three provide standard care. Participants are followed up with patient-reported outcome measures for up to 3 years. The patient-reported outcome measures package comprises EORTC QLQ-C30, EORTC QLQ-OV28, a questionnaire screening tool for recurrence, CollaboRATE, and selected questions from the Patient Experience Questionnaire. MAJOR INCLUSION/EXCLUSION CRITERIA: Patients older than 18 years diagnosed with ovarian, fallopian tube, or primary peritoneal cancer are eligible when entering the follow-up program after primary treatment. Participants must be able to speak and read Danish. SAMPLE SIZE: 223 patients with ovarian cancer. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The protocol closed for enrollment in 2019. Publication of final results is expected in spring 2022. TRIAL REGISTRATION: PROMova was registered with ClinicalTrials.gov November 2016 Identifier: NCT02916875.

AB - BACKGROUND: There is a paucity of high-level evidence on the optimal follow-up of patients with ovarian cancer after primary treatment. A debate is ongoing on the extent to which follow-up should consider patient preferences and patient-reported outcome measures. Incorporation of patient-reported outcome measures supports the dialog between patient and clinician and may be instrumental in symptom monitoring and detection of underlying issues, especially when used actively during the clinical consultation. PRIMARY OBJECTIVE AND ENDPOINT: The PROMova study aims to assess whether proactive use of patient-reported outcome measures during follow-up care increases patient involvement as perceived by the patient compared with standard care. Another objective is to measure satisfaction with the care provided. STUDY HYPOTHESIS: It is hypothesized that proactive use of patient-reported outcome measures during the clinical encounter will improve patients' experience of involvement in follow-up care. TRIAL DESIGN: PROMova is a multi-center, observational cohort study collecting data from eight departments in Denmark. Five departments use the patient-reported outcome measures proactively during the consultation and three provide standard care. Participants are followed up with patient-reported outcome measures for up to 3 years. The patient-reported outcome measures package comprises EORTC QLQ-C30, EORTC QLQ-OV28, a questionnaire screening tool for recurrence, CollaboRATE, and selected questions from the Patient Experience Questionnaire. MAJOR INCLUSION/EXCLUSION CRITERIA: Patients older than 18 years diagnosed with ovarian, fallopian tube, or primary peritoneal cancer are eligible when entering the follow-up program after primary treatment. Participants must be able to speak and read Danish. SAMPLE SIZE: 223 patients with ovarian cancer. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The protocol closed for enrollment in 2019. Publication of final results is expected in spring 2022. TRIAL REGISTRATION: PROMova was registered with ClinicalTrials.gov November 2016 Identifier: NCT02916875.

KW - medical oncology

KW - ovarian cancer

KW - ovarian neoplasms

KW - quality of life (PRO)/palliative care

UR - http://www.scopus.com/inward/record.url?scp=85090505332&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2020-001528

DO - 10.1136/ijgc-2020-001528

M3 - Journal article

C2 - 32586892

AN - SCOPUS:85090505332

VL - 30

SP - 1444

EP - 1449

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -